The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Antiretroviral neurotoxicity
Open accessAbstract
Combination antiretroviral therapy (CART) has proven to effectively suppress systemic HIV burden, however, poor penetration into the central nervous system (CNS) provides incomplete protection. Although the severity of HIV-associated neurocognitive disorders (HAND) has been reduced, neurological disease is expected to exert an increasing burden as HIV-infected patients live longer. Strategies to enhance penetration of antiretroviral compounds into the CNS could help to control HIV replication in this reservoir but also carries an increased risk of neurotoxicity. Efforts to target antiretroviral compounds to the CNS will have to balance these risks against the potential gain. Unfortunately, little information is available on the actions of antiretroviral compounds in the CNS, particularly at concentrations that provide effective virus suppression. The current studies evaluated the direct effects of 15 antiretroviral compounds on neurons to begin to provide basic neurotoxicity data that will serve as a foundation for the development of dosing and drug selection guidelines. Using sensitive indices of neural damage, we found a wide range of toxicities, with median toxic concentrations ranging from 2 to 10,000 ng/ml. Some toxic concentrations overlapped concentrations currently seen in the CSF but the level of toxicity was generally modest at clinically relevant concentrations. Highest neurotoxicities were associated with abacavir, efavarenz, etravirine, nevaripine, and atazanavir, while the lowest were with darunavir, emtracitabine, tenofovir, and maraviroc. No additive effects were seen with combinations used clinically. These data provide initial evidence useful for the development of treatment strategies that might reduce the risk of antiretroviral neurotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Updated research nosology for HIV-associated neurocognitive disorders
Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., Clifford, D. B., Cinque, P., Epstein, L. G., Goodkin, K., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000287431.88658.8b · Cited by 2,630
Self-citationGroups, F. T. C. A. H., Heaton, R. K., Franklin, D. R., Ellis, R. J., McCutchan, J. A., Letendre, S. L., LeBlanc, S., Corkran, S. H., Duarte, N. A., Clifford, D. B., et al. (2011) · Journal of NeuroVirology · doi:10.1007/s13365-010-0006-1 · Cited by 1,533
The prevalence and incidence of neurocognitive impairment in the HAART era
Robertson, K. R., Smurzynski, M., Parsons, T. D., Wu, K., Bosch, R. J., Wu, J., McArthur, J. C., Collier, A. C., Evans, S. R., & Ellis, R. J. (2007) · AIDS · doi:10.1097/qad.0b013e32828e4e27 · Cited by 619
Self-citationKakuda, T. N. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)90004-3 · Cited by 612
HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998
Sacktor, N., Lyles, R. H., Skolasky, R., Kleeberger, C., Selnes, O. A., Miller, E. N., Becker, J. T., Cohen, B., McArthur, J. C., & Study*, T. M. A. C. (2001) · Neurology · doi:10.1212/wnl.56.2.257 · Cited by 591
HIV-associated cognitive impairment before and after the advent of combination therapy
Sacktor, N., McDermott, M. P., Marder, K., Schifitto, G., Selnes, O. A., McArthur, J. C., Stern, Y., Albert, S., Palumbo, D., Kieburtz, K., et al. (2002) · Journal of Neurovirology · doi:10.1080/13550280290049615 · Cited by 584
Takeuchi, H., Mizuno, T., Zhang, G., Wang, J., Kawanokuchi, J., Kuno, R., & Suzumura, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413863200 · Cited by 285 · cited 2×
“Since beading and pruning have been documented under a variety of pathological conditions (Bellizzi et al. 2005; Greenwood et al. 2007; Takeuchi et al. 2005), they most likely reflect a general endpoint associated with neuronal dysfunction (Greenwood et al. 2007; Kim et al. 2010; Masliah et al.…”
BackgroundHDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage
Kim, J. Y., Shen, S., Dietz, K., He, Y., Howell, O., Reynolds, R., & Casaccia, P. (2010) · Nature Neuroscience · doi:10.1038/nn.2471 · Cited by 214
Robertson, K. R., Su, Z., Margolis, D. M., Krambrink, A., Havlir, D. V., Evans, S., & Skiest, D. J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d9ed09 · Cited by 213
Self-citation
Cited by
HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment
Saylor, D., Dickens, A. M., Sacktor, N., Haughey, N., Slusher, B., Pletnikov, M., Mankowski, J. L., Brown, A., Volsky, D. J., & McArthur, J. C. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.27 · Cited by 1,036
HIV-associated neurocognitive disorder
Clifford, D. B., & Ances, B. M. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70269-x · Cited by 670
Controversies in HIV-associated neurocognitive disorders
Nightingale, S., Winston, A., Letendre, S., Michael, B. D., McArthur, J. C., Khoo, S., & Solomon, T. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70137-1 · Cited by 294
Velichkovska, M., Surnar, B., Nair, M., Dhar, S., & Toborek, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01014 · Cited by 49
Role of Dysregulated Autophagy in HIV Tat, Cocaine, and cART Mediated NLRP3 Activation in Microglia
Singh, S., Thangaraj, A., Chivero, E. T., Guo, M.-L., Periyasamy, P., & Buch, S. (2023) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-023-10063-0 · Cited by 12
Metadata
- Authors
- Robertson, K., Liner, J., & Meeker, R. B.
- Venue
- Journal of NeuroVirology
- Published
- 2012-07-19
- Volume
- 18
- Issue
- 5
- Pages
- 388-399
- ISSN
- 1355-0284 (ISSN-L)
- 1538-2443
- OpenAlex
- W3193259242
- Cited by
- 278
- References
- 30
- FWCI
- 12.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiretroviral neurotoxicity. https://app.cochat.ai/papers/10.1007/s13365-012-0120-3
- The paper
- Robertson, K., Liner, J., & Meeker, R. B. (2012). Antiretroviral neurotoxicity. Journal of NeuroVirology. https://doi.org/10.1007/s13365-012-0120-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.